|
|
Blood, 15 September 2004, Vol. 104, No. 6, pp. 1888-1893.
Prepublished online as a Blood First Edition Paper on May 20, 2004; DOI 10.1182/blood-2004-01-0089.
 Previous Article | Table of Contents | Next Article 
TRANSPLANTATION
Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation
David C. Seldin,
Jennifer J. Anderson,
Vaishali Sanchorawala,
Karim Malek,
Daniel G. Wright,
Karen Quillen,
Kathleen T. Finn,
John L. Berk,
Laura M. Dember,
Rodney H. Falk, and
Martha Skinner
From the Amyloid Treatment and Research Program and Stem Cell Transplant Program of the Department of Medicine, and the Department of Pathology, Boston University School of Medicine, Boston, MA; and the Department of Biostatistics, Boston University School of Public Health, Boston, MA.
Treatment of AL amyloidosis patients with high-dose melphalan chemotherapy followed by autologous peripheral blood stem cell transplantation (HDM/SCT) can produce hematologic complete responses (CRs) and improvement in organ function. To determine whether these responses are accompanied by improvement in quality of life (QOL), we employed the Medical Outcomes Study (MOS) 36-item Short Form General Health Survey (SF-36) questionnaire for 544 patients evaluated between 1994 and 2002. At baseline, the scores were significantly lower on all 8 SF-36 scales compared with age-matched population norms: the composite physical component summary (PCS) for the AL patients was 34.5 versus the population norm of 46.8, and the mental component summary (MCS) was 45.0 versus the norm of 51.5. All SF-36 scores improved at 1 year, with the MCS reaching the population norm. The PCS, though improved, was still lower than normal but was greater in the subgroup of patients who achieved a hematologic CR; the PCS normalized at 2 years in these patients. Thus, treatment of AL amyloidosis patients with HDM/SCT produces measurable and sustained improvements in quality of life, particularly in those patients who achieve hematologic CR.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Sharpening therapeutic strategy in AL amyloidosis
- Giampaolo Merlini
Blood 2004 104: 1593-1594.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
T. N. Weingarten, B. A. Hall, B. F. Richardson, R. E. Hofer, and J. Sprung
Periorbital Ecchymoses During General Anesthesia in a Patient with Primary Amyloidosis: A Harbinger for Bleeding?
Anesth. Analg.,
December 1, 2007;
105(6):
1561 - 1563.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Seldin, J. J. Anderson, M. Skinner, K. Malek, D. G. Wright, K. Quillen, K. Finn, B. Oran, and V. Sanchorawala
Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65
Blood,
December 1, 2006;
108(12):
3945 - 3947.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Sanchorawala
Light-Chain (AL) Amyloidosis: Diagnosis and Treatment
Clin. J. Am. Soc. Nephrol.,
November 1, 2006;
1(6):
1331 - 1341.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. H. Vesole, W. S. Perez, M. Akasheh, C. Boudreau, D. E. Reece, C. N. Bredeson, and Plasma Cell Disorders Working Committee of the Cen
High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation for Patients With Primary Systemic Amyloidosis: A Center for International Blood and Marrow Transplant Research Study
Mayo Clin. Proc.,
July 1, 2006;
81(7):
880 - 888.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. V. Rajkumar, A. Dispenzieri, and R. A. Kyle
Monoclonal Gammopathy of Undetermined Significance, Waldenstrom Macroglobulinemia, AL Amyloidosis, and Related Plasma Cell Disorders: Diagnosis and Treatment
Mayo Clin. Proc.,
May 1, 2006;
81(5):
693 - 703.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Comenzo
Light chains ahoy: pirating Thal/Dex for AL too
Blood,
April 1, 2005;
105(7):
2625 - 2625.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Seldin
Interfering with amyloidosis
Blood,
December 1, 2004;
104(12):
3419 - 3420.
[Full Text]
[PDF]
|
|
|
|
|
